- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05530785
Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
An Exploratory Clinical Study of Radiotherapy Combined With Sintilimab Plus Bevacizumab Biosimilar in the Treatment of Unresectable Hepatocellular Carcinoma (uHCC) With Portal Vein Tumor Thrombus (PVTT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
Patients will be performed enhanced CT/MRI every 2 months, to access the efficiency according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, undergoing enhanced CT/MRI. The overall survival (OS) was calculated as the time from enrollment until death or the last follow-up. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 to access the safety.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jia Luo, Professor
- Phone Number: 86-0731-89762031
- Email: luojia@hnca.org.cn
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Recruiting
- Hunan Cancer Hospital
-
Contact:
- Jia Luo, Professor
- Phone Number: +86-0731-89762031
- Email: luojia@hnca.org.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hepatocellular carcinoma confirmed by histology/cytology, or patients with cirrhosis and meet the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria for HCC
- Child-pugh grade A or B (≤7 points)
- A score of 0-1 according to the Eastern Cooperative Oncology Group Physical Status Score (ECOG PS score);
- Barcelona stage C; Inamicable for radical surgical resection or refusal of surgery without extra-hepatic metastases; Portal vein tumor thrombus (PVTT) was diagnosed by enhanced CT or enhanced MRI (type VP1 to VP3).
- Had not received systemic therapy or radiotherapy before; Or disease progression after surgical resection or local treatment (without radiotherapy);
- At least one measurable or evaluable lesion according to the response evaluation criteria for solid tumors, version 1.1 (RECIST V1.1); Or measurable lesions that had clearly progressed after local treatment (based on RECIST V1.1 criteria).
- Patients with liver lesions and/or portal vein tumor thrombus lesions were treated with radiotherapy
Exclusion Criteria:
- Previous histological/cytological diagnosis included fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, and other components.
- The area to be treated had been previously treated with radiotherapy
- Patients with extrahepatic metastases
- Patients with tumor thrombus invasion into the superior mesenteric vein
- Patients with inferior vena cava tumor thrombus.
- Central nervous system metastases were present.
- A history of hepatic encephalopathy, or a history of liver transplantation.
- There are clinical symptoms of pleural effusion, ascites, or pericardial effusion that require drainage.
- Patients with acute or chronic active hepatitis B or C with hepatitis B virus (HBV) DNA>2000IU/ml or 10^4 Copies/ml; Hepatitis C virus (HCV)RNA> 10^3 Copies/ml; Hepatitis B surface antigen (HbsAg) and anti-HCV antibody were both positive.
- History of allergy to active ingredients and/or excipients of anti-PD-1 mab and anti-VEFG mab.
- Other malignancies, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix, were present within 5 years.
- Bleeding events from esophageal or gastric fundus varices due to portal hypertension had occurred within the previous 6 months. Severe (G3) varicose veins were known to have been present on endoscopy within 3 months before the first dose. There was evidence of portal hypertension (including splenomegaly on imaging) and a high risk of bleeding as assessed by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment group
radiotherapy combined with sintilimab and bevacizumab biosimilar
|
After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response rate
Time Frame: up to 2 years from enrollment
|
assessed according to the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1, undergoing enhanced CT/MRI
|
up to 2 years from enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: up to 2 years from enrollment
|
the time from enrollment until death or the last follow-up
|
up to 2 years from enrollment
|
number of participants with treatment-related adverse events
Time Frame: up to 2 years from enrollment
|
number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
up to 2 years from enrollment
|
Objective Response rate, assessed according to the modified Response Evaluation Criteria
Time Frame: up to 2 years from enrollment
|
assessed according to the modified Response Evaluation Criteria in Solid Tumors Version 1.1, undergoing enhanced CT/MRI
|
up to 2 years from enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jia Luo, Professor, Hunan Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- uHCC with PVTT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma Non-resectable
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
Institut für Klinische Krebsforschung IKF GmbH...IpsenRecruitingHepatocellular Carcinoma Non-resectable | Metastatic Hepatocellular CarcinomaGermany
-
Tongji HospitalGeneplus-Beijing Co. Ltd.RecruitingHepatocellular Carcinoma Non-resectableChina
-
Assistance Publique - Hôpitaux de ParisLaboratoire EISAINot yet recruitingHepatocellular Carcinoma Non-resectableFrance
-
Wan-Guang ZhangThe Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaboratorsRecruitingHepatocellular Carcinoma Non-resectableChina
-
Zhujiang HospitalNot yet recruitingHepatocellular Carcinoma Non-resectable
-
Jinan Military General HospitalRecruitingHepatocellular Carcinoma Non-resectableChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHepatocellular Carcinoma Non-ResectableChina
-
Second Affiliated Hospital of Guangzhou Medical...CompletedHepatocellular Carcinoma Non-resectableChina
-
Second Affiliated Hospital of Guangzhou Medical...CompletedHepatocellular Carcinoma Non-resectableChina
Clinical Trials on radiotherapy combined with sintilimab and bevacizumab biosimilar
-
Sun Yat-sen UniversityInnovent Biologics (Suzhou) Co. Ltd.Active, not recruitingHepatocellular CarcinomaChina
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
West China HospitalSichuan Provincial People's Hospital; The First People's Hospital of Ziyang; Chengdu... and other collaboratorsNot yet recruiting
-
Shanghai Chest HospitalRecruitingNon-small Cell Lung Cancer | Minimal Residual Disease | Immunotherapy | Anti-angiogenesisChina
-
Henan Cancer HospitalNot yet recruiting
-
Second Affiliated Hospital of Guangzhou Medical...Active, not recruitingHepatocellular Carcinoma Non-resectableChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Brain NeoplasmUnited States
-
Zhongda HospitalRecruiting
-
West China HospitalRecruiting
-
Sun Yat-sen UniversityNot yet recruitingBreast Cancer | Ipsilateral Supraclavicular Lymph Node Metastasis